Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00932451) enrolled 1,066 people who all received crizotinib 250 mg twice daily. The trial was measuring how a tumour responded over time, including how long any response lasted, how quickly it appeared, and how long participants lived. Of the 1,066 people who started, 244 completed the study and 822 did not complete it (the reasons for not completing were not detailed in the data provided here). The reported data shows a range of measurements across the group. For how long a tumour response lasted (called "duration of response"), the figures reported were 11.8 months and 9.5 months — these likely represent different summary points for the same group, though the data does not clarify further. The time it took for a response to first appear was reported as approximately 6.1 to 6.3 weeks. When looking at whether the disease was controlled (meaning the tumour had shrunk or stopped growing) at 6 weeks and 12 weeks, the reported figures ranged from about 61% to 82% of participants, depending on the time point and the population measured. The reported data shows that the time before the disease worsened or a participant died (progression-free survival) was 8.4 months and 6.9 months. For overall survival — the time from starting treatment until death from any cause — the figures reported were 21.8 months and 16.9 months. The estimated probability of being alive at 6 months was reported as between 77.5% and 81.7%, and at 1 year as between 62.4% and 66.5%. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 30822515) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Lung Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- You have been diagnosed with a type of lung cancer called non-small cell lung cancer, confirmed by a lab test on a tissue or cell sample.
- Your cancer tests positive for a specific gene change called the ALK fusion gene (this can be tested at a central or local laboratory).
- You may have previously taken part in a related clinical trial (A8081007) and received certain chemotherapy drugs (pemetrexed or docetaxel), and stopped because your cancer got worse — or, depending on when you join, you may be able to enroll at any time once results from that earlier trial are available (confirm with trial site).
- Your tumors can be measurable or non-measurable on scans.
Who may not be able to join:
- You have previously been treated with a drug called PF-02341066 (also known as crizotinib).
- You have not received any prior treatment — such as chemotherapy or a specific type of targeted therapy called an EGFR tyrosine kinase inhibitor — for your advanced non-small cell lung cancer.
- You are currently enrolled in another clinical trial that involves a treatment or therapy.
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Objective Response Rate; Percentage of Participants With Adverse Events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.